Insider · CIK 0001520061
Jill Beraud
director
Files at LEVI (LEVI STRAUSS & CO), RVNC (Revance Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 4, 2025 | LEVI LEVI STRAUSS & CO | AGrant or award Class A Common Stock | +85 | $0.00 | $0 | 172,701 | Nov 6, 2025 |
| Nov 4, 2025 | LEVI LEVI STRAUSS & CO | AGrant or award Class B Common Stockderivative | +101 | $0.00 | $0 | 14,196 | Nov 6, 2025 |
| Aug 8, 2025 | LEVI LEVI STRAUSS & CO | AGrant or award Class A Common Stock | +82 | $0.00 | $0 | 172,616 | Aug 12, 2025 |
| Aug 8, 2025 | LEVI LEVI STRAUSS & CO | AGrant or award Class B Common Stockderivative | +97 | $0.00 | $0 | 14,095 | Aug 12, 2025 |
| May 9, 2025 | LEVI LEVI STRAUSS & CO | AGrant or award Class A Common Stock | +88 | $0.00 | $0 | 172,534 | May 12, 2025 |
| May 9, 2025 | LEVI LEVI STRAUSS & CO | AGrant or award Class B Common Stockderivative | +104 | $0.00 | $0 | 13,998 | May 12, 2025 |
| Apr 23, 2025 | LEVI LEVI STRAUSS & CO | CConversion Class A Common Stock | +108,679 | $0.00 | $0 | 160,756 | Apr 25, 2025 |
| Apr 23, 2025 | LEVI LEVI STRAUSS & CO | AGrant or award Class A Common Stock | +11,690 | $0.00 | $0 | 172,446 | Apr 25, 2025 |
| Apr 23, 2025 | LEVI LEVI STRAUSS & CO | CConversion Class B Common Stockderivative | -108,679 | $0.00 | $0 | 13,894 | Apr 25, 2025 |
| Feb 28, 2025 | LEVI LEVI STRAUSS & CO | AGrant or award Class A Common Stock | +56 | $0.00 | $0 | 52,077 | Mar 4, 2025 |
| Feb 28, 2025 | LEVI LEVI STRAUSS & CO | AGrant or award Class B Common Stockderivative | +99 | $0.00 | $0 | 122,573 | Mar 4, 2025 |
| Feb 4, 2025 | RVNC Revance Therapeutics, Inc. | UTender of shares Common Stock | -28,606 | $3.65 | $104k | 15,000 | Feb 6, 2025 |
| Feb 6, 2025 | RVNC Revance Therapeutics, Inc. | DDisposition to issuer Common Stock | -15,000 | - | - | 0 | Feb 6, 2025 |
| Nov 14, 2024 | LEVI LEVI STRAUSS & CO | AGrant or award Class A Common Stock | +60 | $0.00 | $0 | 52,021 | Nov 18, 2024 |
| Nov 14, 2024 | LEVI LEVI STRAUSS & CO | AGrant or award Class B Common Stockderivative | +106 | $0.00 | $0 | 122,474 | Nov 18, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.